(Q34552445)

3 August 2017

title

Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain (English)

1 reference

3 August 2017

0 references

0 references

Miguel Angel Benítez-Rosario

1

1 reference

3 August 2017

Manuel Feria

2

1 reference

3 August 2017

Antonio Salinas-Martín

3

1 reference

3 August 2017

Luis Pedro Martínez-Castillo

4

1 reference

3 August 2017

José Javier Martín-Ortega

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

3 August 2017

1 reference

3 August 2017

volume

101

1 reference

3 August 2017

issue

12

1 reference

3 August 2017

page(s)

2866-2873

1 reference

Strategies to manage the adverse effects of oral morphine: an evidence-based report.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Morphine and alternative opioids in cancer pain: the EAPC recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Opioid rotation for cancer pain: rationale and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Opioid rotation in the management of refractory cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Reversible delirium during opiod switching from transdermal fentanyl to methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Re: Reversible delirium during opioid switching

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Rapid switching from morphine to methadone in cancer patients with poor response to morphine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Methadone use in cancer patients with pain: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Opioid rotation for toxicity reduction in terminal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Hallucinations in an elderly cancer patient: opioid neurotoxicity or dementia with Lewy bodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Visual hallucinations: a prevalence study among hospice inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Methadone in the management of cancer pain: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

Opioid use in cancer pain. Is a more liberal approach enhancing toxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

7 January 2021

The use of methadone for cancer pain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

7 January 2021

Methadone in cancer pain management: individualize dose and titrate to effect

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

7 January 2021

Differential diagnosis of dementia, delirium and depression. Implications for drug therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

7 January 2021

Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

7 January 2021

Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

7 January 2021

Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

7 January 2021

Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

7 January 2021

Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

7 January 2021

Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20712

7 January 2021

Identifiers

DOI

10.1002/CNCR.20712

1 reference

3 August 2017

1 reference